CLAIMS

1. A pharmaceutical composition comprising VS-6063, or a pharmaceutically acceptable salt thereof, admixed with an excipient, wherein the excipient is polyvinylpyrrolidone vinyl acetate copolymer (PVP VA) or a copolymer comprising polyethylene glycol, polyvinylcaprolactam, and polyvinylacetate, wherein the composition is configured in an oral dosage form.

2. The pharmaceutical composition of claim 1, wherein the oral dosage form comprises 5 to 50%, 5 to 30%, 10 to 30%, 10 to 20%, 12 to 15%, or 13% of VS-6063, or a pharmaceutically acceptable salt thereof, per weight of the oral dosage form.

3. The pharmaceutical composition of claim 1, wherein the VS-6063, or a pharmaceutically acceptable salt thereof, is present at 13% weight per weight of the oral dosage form.

4. The pharmaceutical composition of claim 1, wherein the oral dosage form is a tablet.

5. The pharmaceutical composition of claim 4, wherein the tablet is provided by direct compression of a physical blend or mixture.

6. The pharmaceutical composition of claim 5, wherein the physical blend or mixture is provided by a dry granulation process.

7. The pharmaceutical composition of claim 1, further comprising a disintegrant (e.g., a crosslinked polymer, e.g., crosslinked polyvinylpyrrolidone or crospovidone, carboxymethyl cellulose or croscarmellose sodium; modified starch, e.g., sodium starch glycolate).

8. The pharmaceutical composition of claim 7, wherein the disintegrant is a polyvinylpolypyrrolidone (e.g., crospovidone).

9. The pharmaceutical composition of claim 7, wherein the disintegrant is present at 0 to 30%, 5 to 25%, 5 to 20%, 5 to 15%, or 10% per weight of the oral dosage form.

10. The pharmaceutical composition of claim 1, further comprising a lubricant (e.g., talc, silica, fats, e.g., magnesium stearate), optionally wherein the lubricant is magnesium stearate, optionally wherein the lubricant is present at 0.1 to 2%, 0.2 to 1.5%, 1%, or 0.5% per weight of the oral dosage form.

11. The pharmaceutical composition of claim 1, comprising a mixture of two excipients.

12. The pharmaceutical composition of claim 1, further comprising one or more fillers.

13. The pharmaceutical composition of claim 12, wherein the filler is a polyol (e.g., mannitol-starch (e.g., Pearlitol Flash), mannitol, sorbitol).

14. The pharmaceutical composition of claim 1, wherein the composition comprises VS-6063 free base or VS-6063 hydrochloride.

15. An oral dosage form comprising:

VS-6063 (e.g., VS-6063 free base), or a pharmaceutically acceptable salt thereof (e.g., VS-6063 hydrochloride) in an amount from about 10 to 15% by weight on a dry weight basis,

a pharmaceutically acceptable excipient (e.g., a binder (e.g., polyvinyl pyrrolidone (e.g., polyvinyl pyrrolidone vinyl acetate copolymer (PVP/VA), Copovidone)) in an amount from about 15 to 25% by weight on a dry weight basis,

a second pharmaceutically acceptable excipient (e.g., a binder (e.g., polyvinyl actate (e.g., Soluplus))) in an amount from about 15 to 25% by weight on a dry weight basis,

a pharmaceutically acceptable filler (e.g., e.g., polyol (e.g., mannitol-starch (e.g., Pearlitol Flash))) in an amount from about 30 to 40% by weight on a dry weight basis,

a pharmaceutically acceptable disintegrant (e.g., crospovidone in an amount from about 5 to 15% by weight on a dry weight basis, and

a pharmaceutically acceptable lubricant (e.g., magnesium stearate) in an amount from about 0.2 to 1.5% by weight on a dry weight basis.